Skip to main content
    A

    Alaunos Therapeutics Inc (TCRT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.60
    -0.03 (-1.84%)

    Market Cap: $6.86M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Alaunos Therapeutics Inc (TCRT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Alaunos Therapeutics reported revenue of $5.00K for the fiscal year ended Dec 31, 2025, down 50.0% from the year before. That year, net income was -$4.18M with a net margin of -83520.0%, operating cash flow was -$2.87M and free cash flow was -$2.97M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$772.00K.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $6.86M, a compound annual decline of 55.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$5.00K-50.0%100.0%-84500.0%-83520.0%
    Dec 2024$10.00K+100.0%100.0%-48120.0%-46790.0%
    Dec 2023$5.00K-99.8%100.0%-685340.0%-702800.0%
    Dec 2022$2.92M+634.2%100.0%-1201.4%-1291.2%
    Dec 2021$398.00KN/A100.0%-19484.7%-19786.7%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0-100.0%N/AN/AN/A
    Dec 2018$146.00K-97.7%100.0%-36921.9%-36381.5%
    Dec 2017$6.39M-6.9%100.0%-837.3%-850.3%
    Dec 2016$6.86MN/A100.0%-2409.4%-2409.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$5.00K$10.00K$5.00K$2.92M$398.00K$0$0$146.00K$6.39M$6.86M
    Gross profit$5.00K$10.00K$5.00K$2.92M$398.00K$0$0$146.00K$6.39M$6.86M
    Research and development$1.36M$362.00K$16.28M$25.02M$49.64M$52.70M$38.33M$34.13M$45.08M$157.79M
    Operating income-$4.22M-$4.81M-$34.27M-$35.10M-$77.55M-$80.36M-$57.86M-$53.91M-$53.49M-$165.31M
    Net income-$4.18M-$4.68M-$35.14M-$37.73M-$78.75M-$79.98M-$117.80M-$53.12M-$54.32M-$165.30M
    EBITDA-$4.14M-$4.68M-$29.57M-$30.84M-$74.58M-$79.23MN/A-$52.54MN/A-$165.14M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$3.00K$0$0$2.00K$5.00K$0$4.00K$1.00K$1.00K
    Gross profit$0$0$0$3.00K$0$0$2.00K$5.00K$0$4.00K$1.00K$1.00K
    Operating income-$760.00K-$952.00K-$1.01M-$907.00K-$1.19M-$1.04M-$1.09M-$754.00K-$1.15M-$1.17M-$1.74M-$7.95M
    Net income-$772.00K-$952.00K-$1.01M-$893.00K-$1.16M-$1.05M-$1.07M-$741.00K-$1.13M-$1.13M-$1.68M-$7.84M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $1.39M were 46.8% of total assets of $2.97M, against total liabilities of $813.00K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.97M$2.75M$8.26M$64.94M$94.86M$146.34M$109.11M$95.05M$105.61M$106.35M
    Current assets$1.99M$2.75M$8.26M$53.80M$78.83M$130.59M$105.49M$84.28M$90.78M$104.88M
    Cash and equivalents$1.39M$1.09M$6.06M$39.06M$76.05M$115.07M$79.74M$61.73M$70.95M$81.05M
    Total liabilities$813.00K$692.00K$1.96M$26.38M$36.81M$22.36M$14.10M$9.49M$58.42M$58.33M
    Short-term debtN/AN/A$0$16.77M$7.87M$0$774.00KN/AN/AN/A
    Long-term debtN/AN/AN/AN/A$16.25M$0N/AN/AN/AN/A
    Shareholder equity$2.15M$2.06M$6.31M$38.55M$58.06M$123.98M$95.01M$85.56M-$96.81M-$77.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.92M$1.52M$1.88M$2.97M$3.72M$4.74M$2.12M$2.75M$3.55M$4.68M$6.04M$8.26M
    Total liabilities$947.00K$864.00K$595.00K$813.00K$921.00K$1.07M$1.06M$692.00K$826.00K$907.00K$1.24M$1.96M
    Cash and equivalents$615.00K$124.00K$354.00K$1.39M$1.94M$2.88M$319.00K$1.09M$1.68M$2.46M$4.14M$6.06M
    Shareholder equity$971.00K$652.00K$1.29M$2.15M$2.80M$3.66M$1.06M$2.06M$2.72M$3.77M$4.80M$6.31M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$2.87M-$4.97M-$30.14M-$29.23M-$61.47M-$57.01M-$40.85M-$49.46M-$54.67M-$58.33M
    Capital expenditures$98.00K$0$197.00K$216.00K$3.32M$9.78M$284.00K$459.00K$737.00K$551.00K
    Free cash flow-$2.97M-$4.97M-$30.34M-$29.45M-$64.79M-$66.79M-$41.14M-$49.92M-$55.41M-$58.88M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$17.00MN/A$7.12M
    Share repurchasesN/AN/AN/A$45.00K$0$0$653.00K$1.62M$2.06M$1.50M
    Investing cash flow-$98.00K$0$1.35M-$193.00K-$3.32M-$9.78M-$284.00K-$459.00K-$737.00K-$551.00K
    Financing cash flow$3.26M$0-$18.14M$6.37M$25.78M$102.12M$59.15M$40.31M$45.30M-$788.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$425.00K-$300.00K-$1.03M-$552.00K-$844.00K-$701.00K-$772.00K-$592.00K-$781.00K-$1.68M-$1.92M-$7.38M
    Capital expendituresN/AN/A$0$1.00K$97.00K$370.00K$2.25M$0$2.25M$0$0$0
    Free cash flowN/AN/A-$1.03M-$553.00K-$941.00K-$1.07M-$3.02M-$592.00K-$3.03M-$1.68M-$1.92M-$7.38M
    Last 12 quarters

    Frequently Asked Questions About TCRT

    What is Alaunos Therapeutics' annual revenue?

    Alaunos Therapeutics reported revenue of $5.00K for the fiscal year ended Dec 31, 2025.

    How fast is Alaunos Therapeutics' revenue growing?

    Revenue was down 50.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -88.0%.

    Is Alaunos Therapeutics profitable?

    No. Alaunos Therapeutics reported net income of -$4.18M for the fiscal year ended Dec 31, 2025, with a net margin of -83520.0%.

    How much free cash flow does TCRT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$2.87M minus capital expenditures of $98.00K produced free cash flow of -$2.97M.

    How much debt does Alaunos Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $1.39M.